Drugs / MK0731
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00104364 | May 2005 → Jan 2008 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK0731 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00104364 ↗ |
| Action | Inhibit | “a potent inhibitor of KSP” PMID 21424701 ↗ Mar 2011 |
| Route | Intravenous | “patients with advanced solid tumors received MK-0731 intravenously over 24 h every 21 days” PMID 21424701 ↗ Mar 2011 |